Literature DB >> 28785559

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.

Berthold Hocher1,2,3,4, Andreas Pasch5.   

Abstract

BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients.
SUMMARY: In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified. KEY MESSAGE: There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome.

Entities:  

Keywords:  Biomarker; Calcification propensity; Chronic kidney disease-mineral and bone disorder; Morbidity; Mortality; Nonoxidized parathyroid hormone; T50 test

Year:  2017        PMID: 28785559      PMCID: PMC5527176          DOI: 10.1159/000477244

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  69 in total

1.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; G M London
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

2.  Characterization of the parathyrin receptor in renal plasma membranes by labelled hormone and labelled antibody binding techniques.

Authors:  C H McIntosh; R D Hesch
Journal:  Biochim Biophys Acta       Date:  1976-03-19

3.  Interaction of parathyroid hormone with membranes of kidney cortex: degradation of the hormone and activation of adenylate cyclase.

Authors:  L L Chu; L R Forte; C S Anast; D V Cohn
Journal:  Endocrinology       Date:  1975-10       Impact factor: 4.736

4.  Selective uptake of the synthetic amino terminal fragment of bovine parathyroid hormone by isolated perfused bone.

Authors:  K J Martin; J J Freitag; M B Conrades; K A Hruska; S Klahr; E Slatopolsky
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

5.  Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.

Authors:  Dieter Haffner; Berthold Hocher; Dominik Müller; Katja Simon; Kai König; Claus-Michael Richter; Barbara Eggert; Johanna Schwarz; Michael Godes; Richard Nissel; Uwe Querfeld
Journal:  J Hypertens       Date:  2005-05       Impact factor: 4.844

6.  Specific inhibition of long-lasting, L-type calcium channels by synthetic parathyroid hormone.

Authors:  P K Pang; R Wang; J Shan; E Karpinski; C G Benishin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 7.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia.

Authors:  Jonathan Himmelfarb; Peter Stenvinkel; T Alp Ikizler; Raymond M Hakim
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

8.  Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis.

Authors:  Berthold Hocher; Lutz Liefeldt; Thomas Quaschning; Philipp Kalk; Reinhard Ziebig; Michael Godes; Katharina Relle; Gernot Asmus; Johannes-Peter Stasch
Journal:  J Am Soc Nephrol       Date:  2007-02-21       Impact factor: 10.121

9.  Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease.

Authors:  Berthold Hocher; Reinhard Ziebig; Rolfdieter Krause; Gernot Asmus; Hans-H Neumayer; Lutz Liefeldt; Johannes-Peter Stasch
Journal:  Circulation       Date:  2004-05-10       Impact factor: 29.690

10.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Authors:  Jürgen Floege; Joseph Kim; Elizabeth Ireland; Charles Chazot; Tilman Drueke; Angel de Francisco; Florian Kronenberg; Daniele Marcelli; Jutta Passlick-Deetjen; Guntram Schernthaner; Bruno Fouqueray; David C Wheeler
Journal:  Nephrol Dial Transplant       Date:  2010-04-25       Impact factor: 5.992

View more
  3 in total

1.  Clear the Fog around Parathyroid Hormone Assays: What Do iPTH Assays Really Measure?

Authors:  Berthold Hocher; Shufei Zeng
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-05       Impact factor: 8.237

Review 2.  Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.

Authors:  Florian Lang; Christina Leibrock; Lisann Pelzl; Meinrad Gawaz; Burkert Pieske; Ioana Alesutan; Jakob Voelkl
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-04       Impact factor: 5.555

3.  Association of Vitamin D and Parathyroid Hormone with Insulin Sensitivity, Beta Cell Function and Gestational Diabetes in Pregnancy: A Cross-Sectional, Observational Study.

Authors:  Amit Nachankar; Narendra Kotwal; Vimal Upreti; Vishesh Verma; K V S Hari Kumar
Journal:  Diabetes Ther       Date:  2018-09-11       Impact factor: 2.945

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.